eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit
November 22 2021 - 8:00AM
eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company
focused on pioneering the development of selective translation
regulator inhibitors (STRIs) for the treatment of cancer, today
announced that Steve Worland, Ph.D., President and Chief Executive
Officer of eFFECTOR, will participate in a fireside chat at the JMP
Securities Hematology and Oncology Summit on Monday, December 6 at
3:20 p.m. ET.
A live webcast of the event will be available on
the "Events and Presentation" page of the Investors section of the
Company’s website. A replay of the webcast will be available for 30
days following the event. For more information, please visit
investors.effector.com.
About eFFECTOR TherapeuticseFFECTOR is a
clinical-stage biopharmaceutical company focused on pioneering the
development of a new class of oncology drugs referred to as STRIs.
eFFECTOR’s STRI product candidates target the eIF4F complex and its
activating kinase, mitogen-activated protein kinase interacting
kinase (MNK). The eIF4F complex is a central node where two of the
most frequently mutated signaling pathways in cancer, the PI3K-AKT
and RAS-MEK pathways, converge to activate the translation of
select mRNA into proteins that are frequent culprits in key
disease-driving processes. Each of eFFECTOR’s product candidates is
designed to act on a single protein that drives the expression of
multiple functionally related proteins, including oncoproteins and
immunosuppressive proteins in T cells, that together control tumor
growth, survival and immune evasion. eFFECTOR’s lead product
candidate, tomivosertib, is a MNK inhibitor currently being
evaluated in KICKSTART, a randomized, double-blind,
placebo-controlled Phase 2b trial of tomivosertib in combination
with pembrolizumab in patients with metastatic non-small cell lung
cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is
currently being evaluated in Phase 2a expansion cohorts in certain
biomarker-positive solid tumors, including ER+ breast cancer and
KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer
to develop inhibitors of a third target, eIF4E. In addition to the
company’s oncology focus, zotatifin is being evaluated as a
potential host-directed anti-viral therapy in patients with mild to
moderate COVID-19 in collaboration with the University of
California, San Francisco, under a $5 million grant sponsored by
the Defense Advanced Research Projects Agency.
Contacts:
Investors:
Stephanie CarringtonWestwicke, an ICR
Company646-277-1282Stephanie.Carrington@westwicke.com
Media:
Heidi Chokeir, Ph.D.Canale
Communications619-203-5391heidi.chokeir@canalecomm.com
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Apr 2023 to Apr 2024